MX2017010516A - Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea. - Google Patents

Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea.

Info

Publication number
MX2017010516A
MX2017010516A MX2017010516A MX2017010516A MX2017010516A MX 2017010516 A MX2017010516 A MX 2017010516A MX 2017010516 A MX2017010516 A MX 2017010516A MX 2017010516 A MX2017010516 A MX 2017010516A MX 2017010516 A MX2017010516 A MX 2017010516A
Authority
MX
Mexico
Prior art keywords
diagnosis
prognosis
cornea
subject
biomarkers
Prior art date
Application number
MX2017010516A
Other languages
English (en)
Inventor
Campos Perez Francisco
Isabel LEMA GESTO María
Antonio CASTILLO SÁNCHEZ José
Sobrino Moreiras Tomás
Original Assignee
Univ Santiago Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Santiago Compostela filed Critical Univ Santiago Compostela
Publication of MX2017010516A publication Critical patent/MX2017010516A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención se refiere al campo de los métodos de diagnóstico y pronóstico de patologías moleculares. En particular, la invención se refiere a métodos para determinar el diagnóstico de una enfermedad ectásica de la córnea en un sujeto, para determinar el riesgo de desarrollar una enfermedad ectásica de la córnea en un sujeto, para determinar el desenlace clínico de un sujeto que padece una enfermedad ectásica de la córnea y para seleccionar un sujeto que va a tratarse con una terapia para una enfermedad ectásica de la córnea basándose en la determinación de los niveles de expresión de los marcadores TLR2 y/o TLR4. La invención también se refiere al uso de TLR2 y/o TLR4 como marcadores de diagnóstico y pronóstico para una enfermedad ectásica de la córnea.
MX2017010516A 2015-02-16 2016-02-16 Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea. MX2017010516A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382060.0A EP3056906A1 (en) 2015-02-16 2015-02-16 Biomarkers for diagnosis and prognosis of corneal ectasia
PCT/EP2016/053293 WO2016131840A1 (en) 2015-02-16 2016-02-16 Biomarkers for diagnosis and prognosis of corneal ectatic disorders

Publications (1)

Publication Number Publication Date
MX2017010516A true MX2017010516A (es) 2018-06-15

Family

ID=52589323

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010516A MX2017010516A (es) 2015-02-16 2016-02-16 Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea.
MX2020006388A MX2020006388A (es) 2015-02-16 2017-08-15 Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020006388A MX2020006388A (es) 2015-02-16 2017-08-15 Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.

Country Status (13)

Country Link
US (2) US10914746B2 (es)
EP (3) EP3056906A1 (es)
JP (1) JP6904908B2 (es)
KR (1) KR102495060B1 (es)
AU (1) AU2016221761A1 (es)
CA (1) CA2975951C (es)
DK (1) DK3259599T3 (es)
ES (1) ES2764456T3 (es)
HK (1) HK1248810A1 (es)
MX (2) MX2017010516A (es)
PT (1) PT3259599T (es)
SG (1) SG11201706249RA (es)
WO (1) WO2016131840A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6707239B1 (ja) 2019-03-13 2020-06-10 株式会社中京メディカル 円錐角膜判定装置及びプログラム
KR102287259B1 (ko) * 2019-08-27 2021-08-06 주식회사 비쥬웍스 원추 각막 진단 보조 시스템 및 이를 이용하는 방법
CN113009158B (zh) * 2021-04-30 2023-07-25 天津市眼科医院 中高度近视的辅助诊断标记物及其用途
US11406531B1 (en) * 2021-07-24 2022-08-09 Peter S. Hersh Method for the amelioration of ectatic and irregular corneal disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7370969B2 (en) * 2004-03-31 2008-05-13 Nidek Co., Ltd. Corneal topography analysis system
GB0601959D0 (en) * 2006-01-31 2006-03-15 King S College London Sepsis test
US20070248970A1 (en) * 2006-03-24 2007-10-25 Eye Birth Defects Research Foundation Compositions and methods for detecting keratoconus
EP2507394A4 (en) * 2009-12-02 2013-06-12 Univ Sydney DIAGNOSTIC AND THERAPEUTIC METHODS FOR KERATECTASIS FOLLOWING REFRACTIVE SURGERY, KERATOCON OR PELLUCID DEGENERATION
KR20130027281A (ko) * 2011-09-07 2013-03-15 (주)에스엘에스 원추각막 검사 방법 및 키트
WO2013107826A2 (en) * 2012-01-17 2013-07-25 Institut Pasteur Use of cellular biomarkers expression to diagnose sepsis among intensive care patients
WO2014106833A1 (en) * 2013-01-07 2014-07-10 Singapore Health Services Pte Ltd A process for identification of biomarkers for keratoconus progression

Also Published As

Publication number Publication date
AU2016221761A1 (en) 2017-09-28
CA2975951A1 (en) 2016-08-25
SG11201706249RA (en) 2017-08-30
MX2020006388A (es) 2020-09-17
CA2975951C (en) 2023-02-14
EP3259599B1 (en) 2019-10-02
US20180067128A1 (en) 2018-03-08
PT3259599T (pt) 2020-01-27
KR102495060B1 (ko) 2023-02-02
US10914746B2 (en) 2021-02-09
EP3056906A1 (en) 2016-08-17
US20210132084A1 (en) 2021-05-06
EP3259599A1 (en) 2017-12-27
WO2016131840A1 (en) 2016-08-25
ES2764456T3 (es) 2020-06-03
JP2018510651A (ja) 2018-04-19
JP6904908B2 (ja) 2021-07-21
HK1248810A1 (zh) 2018-10-19
KR20170138400A (ko) 2017-12-15
EP3608675A1 (en) 2020-02-12
DK3259599T3 (da) 2020-01-13

Similar Documents

Publication Publication Date Title
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
TW201613637A (en) Methods of treating Alzheimer's Disease
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
WO2016077366A8 (en) Therapeutic and diagnostic methods for il-33-mediated disorders
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
MX351428B (es) Métodos in vitro para correlacionar el nivel de sr2 solubre y la eficiencia de terapia de ejercicio en un sujeto que tiene una enfermedad cardiovascular.
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
MX2015009392A (es) Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2017004742A (es) Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
EA201700123A1 (ru) Способ прогнозирования варианта лекарственного препарата для лечения депрессии
EP4286847A3 (en) Genetic abnormalities in plasma cell dyscrasias
EA201890649A1 (ru) Новые биомаркеры и способы лечения рака
EA202090673A1 (ru) Стратификация генотипа при лечении и профилактике диабета
BR112017008805A2 (pt) tratamento de córnea usando laminina
EA201491780A1 (ru) Мутанты c-raf, придающие резистентность к ингибиторам raf
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
MX2017014540A (es) Biomarcadores para una terapia combinada que comprende lenvatinib y everolimus.
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
EP4289970A3 (en) Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis
EA201891693A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови
MX2018006250A (es) Biomarcador de enfermedad poliquistica renal y usos del mismo.

Legal Events

Date Code Title Description
FG Grant or registration